COVID-19: Considerations of Diabetes and Cardiovascular Disease Management

J Diabetes Sci Technol. 2020 Jul;14(4):723-724. doi: 10.1177/1932296820930025. Epub 2020 May 30.
No abstract available

Keywords: COVID-19; SARS -CoV-2; continuous glucose monitoring; diabetes; glucose variability; intensive care unit; telemedicine.

MeSH terms

  • Angiotensin-Converting Enzyme 2
  • Betacoronavirus*
  • Blood Glucose / metabolism
  • COVID-19
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / therapy*
  • Comorbidity
  • Coronavirus Infections / epidemiology*
  • Diabetes Complications / epidemiology*
  • Diabetes Complications / therapy
  • Diabetes Mellitus / epidemiology
  • Diabetes Mellitus / therapy*
  • Diabetic Cardiomyopathies / epidemiology
  • Diabetic Cardiomyopathies / therapy
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use
  • Intensive Care Units
  • Pandemics*
  • Peptidyl-Dipeptidase A / drug effects
  • Pneumonia, Viral / epidemiology*
  • SARS-CoV-2

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2